Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 14:09:15 GMT 2023
by
admin
on
Sat Dec 16 14:09:15 GMT 2023
|
Protein Type | RECEPTOR |
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
4R3XO922WS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4R3XO922WS
Created by
admin on Sat Dec 16 14:09:18 GMT 2023 , Edited by admin on Sat Dec 16 14:09:18 GMT 2023
|
PRIMARY | |||
|
NMDA receptor antagonist
Created by
admin on Sat Dec 16 14:09:18 GMT 2023 , Edited by admin on Sat Dec 16 14:09:18 GMT 2023
|
PRIMARY |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_43 |
N | 1_185 |
N | 1_221 |
N | 1_258 |
N | 1_282 |
N | 1_332 |
N | 1_350 |
N | 1_422 |
N | 1_453 |
N | 1_473 |
N | 1_753 |
N | 2_43 |
N | 2_185 |
N | 2_221 |
N | 2_258 |
N | 2_282 |
N | 2_332 |
N | 2_350 |
N | 2_422 |
N | 2_453 |
N | 2_473 |
N | 2_753 |
N | 3_53 |
N | 3_318 |
N | 3_358 |
N | 3_421 |
N | 3_519 |
N | 3_592 |
N | 3_665 |
N | 3_864 |
N | 3_881 |
N | 3_889 |
N | 3_924 |
N | 3_967 |
N | 3_1019 |
N | 3_1116 |
N | 3_1188 |
N | 3_1375 |
N | 4_48 |
N | 4_315 |
N | 4_322 |
N | 4_418 |
N | 4_465 |
N | 4_516 |
N | 4_589 |
N | 4_662 |
N | 4_866 |
N | 4_884 |
N | 4_889 |
N | 4_1149 |
N | 4_1174 |
N | 4_1198 |
N | 4_1249 |
N | 4_1326 |
N | 4_1424 |
N | 4_1440 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Channel blocker
UNCOMPETITIVE
Ki
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Blocks glutamate binding.
COMPETITIVE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
COMPETITIVE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
WEAK INHIBITOR->TARGET |
Rat. Prodrug of dextrorphan, which is the actual mediator of most of its dissociative effects through acting as a more potent NMDA receptor antagonist than dextromethorphan itself.
Ki
|
||
|
INHIBITOR -> TARGET |
Binds to glutamate site
COMPETITIVE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
COMPETITIVE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
MODULATOR->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
PARTIAL AGONIST->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
MODULATOR->TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
positive allosteric modulator of NMDA receptors
ALLOSTERIC
|
||
|
INHIBITOR -> TARGET |
Competes with glutamate
COMPETITIVE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
Channel blocker
UNCOMPETITIVE
Ki
|
||
|
INHIBITOR -> TARGET |
Noncompetitive antagonists at the NMDA receptor via binding to an allosteric site distinct from the glutamate-binding site.This receptor is a critical modulator of CNS neurotransmission, and excitability changes produced by ketamine antagonism may explain the drug’s anesthetic and analgesic properties.
ALLOSTERIC INHIBITOR
Ki
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
COMPETITIVE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
Active as an NMDA receptor antagonist in the central nervous system at roughly 30 times the potency of the "flagship" of its class, ketamine.
Ki
|
||
|
INHIBITOR -> TARGET |
NON-COMPETITIVE
IC50
|
||
|
INHIBITOR -> TARGET |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|